Juan Chen1, Xiaoyan Shi2, Lan Xiao1, Zelian Li1, Zhimin Li3, Lei Sun1. 1. Department of Obstetrics & Gynecology, First Affiliated Hospital of Anhui Medical University, Hefei, China. 2. Central Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Department of Gynecology, Guangdong Women and Children Hospital, Guangzhou, China.
Abstract
BACKGROUND: Tumor characteristics can be prognostically relevant in patients with high-grade serous ovarian carcinoma (HGSOC). This study aimed to determine whether different subtypes of HGSOC, especially the mesenchymal subtype, are associated with overall survival (OS) or progression-free survival (PFS) in patients with HGSOC. METHODS: PubMed, Embase, and the Cochrane Library were searched for studies published up to September 2020. The eligibility criteria were (1) population: patients with HGSOG with molecular subtyping of their tumor, (2) exposure: mesenchymal subtype, (3) non-exposure: differentiated, immunoreactive, proliferative, and other non-mesenchymal subtypes, (4) outcome: survival, with hazard ratios (HRs), and (5) English language. RESULTS: The mesenchymal subtype showed no statistically significant difference in OS compared with the immunoreactive subtype (HR = 1.47, 95% CI: 0.78-2.78, p = 0.238; I2 = 81.2%, pheterogeneity = 0.005) or all non-mesenchymal subtypes (HR = 1.65, 95% CI: 0.97-2.80, p = 0.063; I2 = 79.4%, pheterogeneity = 0.008). The mesenchymal subtype showed no statistically significant difference in PFS compared with the immunoreactive subtype (HR = 1.19, 95% CI: 0.71-2.00, p = 0.514; I2 = 71.6%, pheterogeneity = 0.030) but a significant differences was observed when using all non-mesenchymal subtypes as reference (HR = 1.51, 95% CI: 1.00-2.28, p = 0.049). The results were robust according to the sensitivity analyses. CONCLUSIONS: There are no statistically significant differences in OS between the mesenchymal subtype of HGSOC and other subtypes of HGSOC. Because of statistical power, this meta-analysis cannot conclude about non-inferiority, and the relationship between the molecular subtypes and HGSOC prognosis remains controversial. Based on one study, the mesenchymal subtype could have a poorer PFS than the non-mesenchymal subtypes of HGSOC, but this conclusion requires further evidence.
BACKGROUND: Tumor characteristics can be prognostically relevant in patients with high-grade serous ovarian carcinoma (HGSOC). This study aimed to determine whether different subtypes of HGSOC, especially the mesenchymal subtype, are associated with overall survival (OS) or progression-free survival (PFS) in patients with HGSOC. METHODS: PubMed, Embase, and the Cochrane Library were searched for studies published up to September 2020. The eligibility criteria were (1) population: patients with HGSOG with molecular subtyping of their tumor, (2) exposure: mesenchymal subtype, (3) non-exposure: differentiated, immunoreactive, proliferative, and other non-mesenchymal subtypes, (4) outcome: survival, with hazard ratios (HRs), and (5) English language. RESULTS: The mesenchymal subtype showed no statistically significant difference in OS compared with the immunoreactive subtype (HR = 1.47, 95% CI: 0.78-2.78, p = 0.238; I2 = 81.2%, pheterogeneity = 0.005) or all non-mesenchymal subtypes (HR = 1.65, 95% CI: 0.97-2.80, p = 0.063; I2 = 79.4%, pheterogeneity = 0.008). The mesenchymal subtype showed no statistically significant difference in PFS compared with the immunoreactive subtype (HR = 1.19, 95% CI: 0.71-2.00, p = 0.514; I2 = 71.6%, pheterogeneity = 0.030) but a significant differences was observed when using all non-mesenchymal subtypes as reference (HR = 1.51, 95% CI: 1.00-2.28, p = 0.049). The results were robust according to the sensitivity analyses. CONCLUSIONS: There are no statistically significant differences in OS between the mesenchymal subtype of HGSOC and other subtypes of HGSOC. Because of statistical power, this meta-analysis cannot conclude about non-inferiority, and the relationship between the molecular subtypes and HGSOC prognosis remains controversial. Based on one study, the mesenchymal subtype could have a poorer PFS than the non-mesenchymal subtypes of HGSOC, but this conclusion requires further evidence.
Authors: Daniel Newsted; Sunandan Banerjee; Kathleen Watt; Sarah Nersesian; Peter Truesdell; Levi L Blazer; Lia Cardarelli; Jarrett J Adams; Sachdev S Sidhu; Andrew W Craig Journal: Oncoimmunology Date: 2018-11-20 Impact factor: 8.110
Authors: Chen Wang; Sebastian M Armasu; Kimberly R Kalli; Matthew J Maurer; Ethan P Heinzen; Gary L Keeney; William A Cliby; Ann L Oberg; Scott H Kaufmann; Ellen L Goode Journal: Clin Cancer Res Date: 2017-03-09 Impact factor: 12.531